The DOI matches its Crossref record; 36 of the 36 references it cites were found in a registry or an index.
Phage Therapy in Clinical Practice: Treatment of Human Infections
Abstract
Phage therapy is the application of bacteria-specific viruses with the goal of reducing or eliminating pathogenic or nuisance bacteria. While phage therapy has become a broadly relevant technology, including veterinary, agricultural, and food microbiology applications, it is for the treatment or prevention of human infections that phage therapy first caught the world's imagination--see, especially, Arrowsmith by Sinclair Lewis (1925)--and which today is the primary motivator of the field. Nonetheless, though the first human phage therapy took place in the 1920s, by the 1940s the field, was in steep decline despite early promise. The causes were at least three-fold: insufficient understanding among researchers of basic phage biology; over exuberance, which led, along with ignorance, to carelessness; and the advent of antibiotics, an easier to handle as well as highly powerful category of antibacterials. The decline in phage therapy was neither uniform nor complete, especially in the former Soviet Republic of Georgia, where phage therapy traditions and practice continue to this day. In this review we strive toward three goals: 1. To provide an overview of the potential of phage therapy as a means of treating or preventing human diseases; 2. To explore the phage therapy state of the art as currently practiced by physicians in various pockets of phage therapy activity around the world, including in terms of potential commercialization; and 3. To avert a recapitulation of phage therapy's early decline by outlining good practices in phage therapy practice, experimentation, and, ultimately, commercialization.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Church, D., Elsayed, S., Reid, O., Winston, B., & Lindsay, R. (2006) · Clinical Microbiology Reviews · doi:10.1128/cmr.19.2.403-434.2006 · Cited by 1,876
Wright, A., Hawkins, C. H., Änggård, E. E., & Harper, D. R. (2009) · Clinical Otolaryngology · doi:10.1111/j.1749-4486.2009.01973.x · Cited by 864
Bacteriophage Host Range and Bacterial Resistance
Hyman, P., & Abedon, S. T. (2010) · Advances in Applied Microbiology · doi:10.1016/s0065-2164(10)70007-1 · Cited by 819
Self-citationPolicing stabilizes construction of social niches in primates
Flack, J. C., Girvan, M., de Waal, F. B. M., & Krakauer, D. C. (2006) · Nature · doi:10.1038/nature04326 · Cited by 718
Human Volunteers Receiving Escherichia coli Phage T4 Orally: a Safety Test of Phage Therapy
Bruttin, A., & Brüssow, H. (2005) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.49.7.2874-2878.2005 · Cited by 563
Merabishvili, M., Pirnay, J.-P., Verbeken, G., Chanishvili, N., Tediashvili, M., Lashkhi, N., Glonti, T., Krylov, V., Mast, J., Van Parys, L., et al. (2009) · PLoS ONE · doi:10.1371/journal.pone.0004944 · Cited by 511
Self-citationPhage Choice, Isolation, and Preparation for Phage Therapy
Gill, J., & Hyman, P. (2010) · Current Pharmaceutical Biotechnology · doi:10.2174/138920110790725311 · Cited by 441
Abedon, S., & Thomas-Abedon, C. (2010) · Current Pharmaceutical Biotechnology · doi:10.2174/138920110790725410 · Cited by 284
Self-citationMarkoishvili, K., Tsitlanadze, G., Katsarava, R., Glenn, J., Morris Jr., M. D., & Sulakvelidze, A. (2002) · International Journal of Dermatology · doi:10.1046/j.1365-4362.2002.01451.x · Cited by 243
Bacteriophage penetration in vertebrates
Dabrowska, K., Switala-Jelen, K., Opolski, A., Weber-Dabrowska, B., & Gorski, A. (2005) · Journal of Applied Microbiology · doi:10.1111/j.1365-2672.2004.02422.x · Cited by 240
Cited by
Pros and cons of phage therapy
Loc-Carrillo, C., & Abedon, S. T. (2011) · Bacteriophage · doi:10.4161/bact.1.2.14590 · Cited by 1,020
Self-citationPhage Therapy in the Postantibiotic Era
Gordillo Altamirano, F. L., & Barr, J. J. (2019) · Clinical Microbiology Reviews · doi:10.1128/cmr.00066-18 · Cited by 998
Phage treatment of human infections
Abedon, S. T., Kuhl, S. J., Blasdel, B. G., & Kutter, E. M. (2011) · Bacteriophage · doi:10.4161/bact.1.2.15845 · Cited by 980
Self-citationPhage Cocktails and the Future of Phage Therapy
Chan, B. K., Abedon, S. T., & Loc-Carrillo, C. (2013) · Future Microbiology · doi:10.2217/fmb.13.47 · Cited by 914
Self-citationJault, P., Leclerc, T., Jennes, S., Pirnay, J. P., Que, Y.-A., Resch, G., Rousseau, A. F., Ravat, F., Carsin, H., Le Floch, R., et al. (2019) · The Lancet Infectious Diseases · doi:10.1016/s1473-3099(18)30482-1 · Cited by 874
Alternatives to Conventional Antibiotics in the Era of Antimicrobial Resistance
Ghosh, C., Sarkar, P., Issa, R., & Haldar, J. (2019) · Trends in Microbiology · doi:10.1016/j.tim.2018.12.010 · Cited by 661
Expansion of Bacteriophages Is Linked to Aggravated Intestinal Inflammation and Colitis
Gogokhia, L., Buhrke, K., Bell, R., Hoffman, B., Brown, D. G., Hanke-Gogokhia, C., Ajami, N. J., Wong, M. C., Ghazaryan, A., Valentine, J. F., et al. (2019) · Cell Host & Microbe · doi:10.1016/j.chom.2019.01.008 · Cited by 609
Self-citationWittebole, X., De Roock, S., & Opal, S. M. (2014) · Virulence · doi:10.4161/viru.25991 · Cited by 599
Bacteriophage-encoded depolymerases: their diversity and biotechnological applications
Pires, D. P., Oliveira, H., Melo, L. D. R., Sillankorva, S., & Azeredo, J. (2016) · Applied Microbiology and Biotechnology · doi:10.1007/s00253-015-7247-0 · Cited by 517
Khan Mirzaei, M., & Nilsson, A. S. (2015) · PLOS ONE · doi:10.1371/journal.pone.0118557 · Cited by 516
Bacteriophages as potential new therapeutics to replace or supplement antibiotics
Kutateladze, M., & Adamia, R. (2010) · Trends in Biotechnology · doi:10.1016/j.tibtech.2010.08.001 · Cited by 483
Phage Choice, Isolation, and Preparation for Phage Therapy
Gill, J., & Hyman, P. (2010) · Current Pharmaceutical Biotechnology · doi:10.2174/138920110790725311 · Cited by 441
Yehl, K., Lemire, S., Yang, A. C., Ando, H., Mimee, M., Torres, M. D. T., de la Fuente-Nunez, C., & Lu, T. K. (2019) · Cell · doi:10.1016/j.cell.2019.09.015 · Cited by 437
Genetically Engineered Phages: a Review of Advances over the Last Decade
Pires, D. P., Cleto, S., Sillankorva, S., Azeredo, J., & Lu, T. K. (2016) · Microbiology and Molecular Biology Reviews · doi:10.1128/mmbr.00069-15 · Cited by 427
Phage Therapy—History from Twort and d'Herelle Through Soviet Experience to Current Approaches
Chanishvili, N. (2012) · Advances in Virus Research · doi:10.1016/b978-0-12-394438-2.00001-3 · Cited by 407
Dąbrowska, K. (2019) · Medicinal Research Reviews · doi:10.1002/med.21572 · Cited by 375
Bacteriophage for Biocontrol of Foodborne Pathogens: Calculations and Considerations
Hagens, S., & Loessner, M. (2010) · Current Pharmaceutical Biotechnology · doi:10.2174/138920110790725429 · Cited by 366
Bacteriophage Therapy: Clinical Trials and Regulatory Hurdles
Furfaro, L. L., Payne, M. S., & Chang, B. J. (2018) · Frontiers in Cellular and Infection Microbiology · doi:10.3389/fcimb.2018.00376 · Cited by 362
Harper, D., Parracho, H., Walker, J., Sharp, R., Hughes, G., Werthén, M., Lehman, S., & Morales, S. (2014) · Antibiotics · doi:10.3390/antibiotics3030270 · Cited by 342
Leitner, L., Ujmajuridze, A., Chanishvili, N., Goderdzishvili, M., Chkonia, I., Rigvava, S., Chkhotua, A., Changashvili, G., McCallin, S., Schneider, M. P., et al. (2021) · The Lancet Infectious Diseases · doi:10.1016/s1473-3099(20)30330-3 · Cited by 322
Biotechnological applications of bacteriophages: State of the art
Harada, L. K., Silva, E. C., Campos, W. F., Del Fiol, F. S., Vila, M., Dąbrowska, K., Krylov, V. N., & Balcão, V. M. (2018) · Microbiological Research · doi:10.1016/j.micres.2018.04.007 · Cited by 318
The Prevalence and Control of Bacillus and Related Spore-Forming Bacteria in the Dairy Industry
Gopal, N., Hill, C., Ross, P. R., Beresford, T. P., Fenelon, M. A., & Cotter, P. D. (2015) · Frontiers in Microbiology · doi:10.3389/fmicb.2015.01418 · Cited by 316
Revisiting phage therapy: new applications for old resources
Nobrega, F. L., Costa, A. R., Kluskens, L. D., & Azeredo, J. (2015) · Trends in Microbiology · doi:10.1016/j.tim.2015.01.006 · Cited by 310
Mammalian Host-Versus-Phage immune response determines phage fate in vivo
Hodyra-Stefaniak, K., Miernikiewicz, P., Drapała, J., Drab, M., Jończyk-Matysiak, E., Lecion, D., Kaźmierczak, Z., Beta, W., Majewska, J., Harhala, M., et al. (2015) · Scientific Reports · doi:10.1038/srep14802 · Cited by 302
The Phage Therapy Paradigm: Prêt-à-Porter or Sur-mesure?
Pirnay, J.-P., De Vos, D., Verbeken, G., Merabishvili, M., Chanishvili, N., Vaneechoutte, M., Zizi, M., Laire, G., Lavigne, R., Huys, I., et al. (2011) · Pharmaceutical Research · doi:10.1007/s11095-010-0313-5 · Cited by 298
Self-citationEarly clinical experience of bacteriophage therapy in 3 lung transplant recipients
Aslam, S., Courtwright, A. M., Koval, C., Lehman, S. M., Morales, S., Furr, C.-L. L., Rosas, F., Brownstein, M. J., Fackler, J. R., Sisson, B. M., et al. (2019) · American Journal of Transplantation · doi:10.1111/ajt.15503 · Cited by 285
Abedon, S., & Thomas-Abedon, C. (2010) · Current Pharmaceutical Biotechnology · doi:10.2174/138920110790725410 · Cited by 284
Self-citationTherapeutic Strategies for Emerging Multidrug-Resistant Pseudomonas aeruginosa
Kunz Coyne, A. J., El Ghali, A., Holger, D., Rebold, N., & Rybak, M. J. (2022) · Infectious Diseases and Therapy · doi:10.1007/s40121-022-00591-2 · Cited by 275
Alternatives to overcoming bacterial resistances: State-of-the-art
Rios, A. C., Moutinho, C. G., Pinto, F. C., Del Fiol, F. S., Jozala, A., Chaud, M. V., Vila, M. M. D. C., Teixeira, J. A., & Balcão, V. M. (2016) · Microbiological Research · doi:10.1016/j.micres.2016.04.008 · Cited by 263
Drulis-Kawa, Z., Majkowska-Skrobek, G., Maciejewska, B., Delattre, A.-S., & Lavigne, R. (2012) · Current Protein & Peptide Science · doi:10.2174/138920312804871193 · Cited by 261
Bacteriophage therapy as an alternative treatment for human infections. A comprehensive review
Kakasis, A., & Panitsa, G. (2019) · International Journal of Antimicrobial Agents · doi:10.1016/j.ijantimicag.2018.09.004 · Cited by 261
Maciejewska, B., Olszak, T., & Drulis-Kawa, Z. (2018) · Applied Microbiology and Biotechnology · doi:10.1007/s00253-018-8811-1 · Cited by 222
Clinical translation of microbe‐based therapies: Current clinical landscape and preclinical outlook
Vargason, A. M., & Anselmo, A. C. (2018) · Bioengineering & Translational Medicine · doi:10.1002/btm2.10093 · Cited by 71
“, intestinal lumen) to continue this cycle.(20) Phages are highly specific to bacterial strains and can be used to exclusively eliminate enteric pathogens, while sparing commensal bacteria; this has motivated research into their use for the treatment of antibioticresistant pathogens.”
BackgroundThe applications of animal models in phage therapy: An update
Mehmood Khan, F., Manohar, P., Singh Gondil, V., Mehra, N., Kayode Oyejobi, G., Odiwuor, N., Ahmad, T., & Huang, G. (2023) · Human Vaccines & Immunotherapeutics · doi:10.1080/21645515.2023.2175519 · Cited by 32
Mutalik, V. K., & Arkin, A. P. (2022) · iScience · doi:10.1016/j.isci.2022.104121 · Cited by 32
Metadata
- Authors
- Kutter, E., De Vos, D., Gvasalia, G., Alavidze, Z., Gogokhia, L., Kuhl, S., & Abedon, S.
- Venue
- Current Pharmaceutical Biotechnology
- Publisher
- Bentham Science Publishers Ltd.
- Published
- 2010-01-01
- Volume
- 11
- Issue
- 1
- Pages
- 69-86
- ISSN
- 1389-2010 (ISSN-L)
- OpenAlex
- W2117840807
- Cited by
- 670
- References
- 36
- FWCI
- 19.88
- Type
- journal article
- Language
- en
- Open access
- closed
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.